Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA

Self-amplifying mRNA (saRNA) represents a promising platform for nucleic acid delivery of vaccine immunogens. Unlike plasmid DNA, saRNA does not require entry into the nucleus of target cells for expression, having the capacity to drive higher protein expression compared to mRNA as it replicates wit...

Full description

Bibliographic Details
Main Authors: Yoann Aldon, Paul F. McKay, Jorge Moreno Herrero, Annette B. Vogel, Réka Lévai, Pauline Maisonnasse, Nathalie Dereuddre-Bosquet, Heinrich Haas, Katalin Fábián, Roger Le Grand, Ugur Sahin, Robin J. Shattock
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
HIV
Env
PEI
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253121001499
Description
Summary:Self-amplifying mRNA (saRNA) represents a promising platform for nucleic acid delivery of vaccine immunogens. Unlike plasmid DNA, saRNA does not require entry into the nucleus of target cells for expression, having the capacity to drive higher protein expression compared to mRNA as it replicates within the cytoplasm. In this study, we examined the potential of stabilized native-like HIV-1 Envelope glycoprotein (Env) trimers to elicit immune responses when delivered by saRNA polyplexes (PLXs), assembled with linear polyethylenimine. We showed that Venezuelan equine encephalitis virus (VEEV) saRNA induces a stronger humoral immune response to the encoded transgene compared to Semliki Forest virus saRNA. Moreover, we characterized the immunogenicity of the soluble and membrane-bound ConSOSL.UFO Env design in mice and showed a faster humoral kinetic and an immunoglobulin G (IgG)2a skew using a membrane-bound design. The immune response generated by PLX VEEV saRNA encoding the membrane-bound Env was then evaluated in larger animal models including macaques, in which low doses induced high IgG responses. Our data demonstrated that the VEEV saRNA PLX nanoparticle formulation represents a suitable platform for the delivery of stabilized HIV-1 Env and has the potential to be used in a variety of vaccine regimens.
ISSN:2162-2531